Background: There are limited evidence-based data to guide treatment recommendations for breast cancer (BC) patients ≥80 years (P80+). Identifying and addressing unmet needs are critical. Aims: Advocate-BREAST80+ compared the needs of P80+ vs. patients < 80 years (P80−). Methods: In 12/2021, a REDCap survey was electronically circulated to 6918 persons enrolled in the Mayo Clinic Breast Disease Registry. The survey asked about concerns and satisfaction with multiple aspects of BC care. Results: Overall, 2437 participants responded (35% response rate); 202 (8.3%) were P80+. P80+ were less likely to undergo local regional and systemic therapies vs. P80− (p< 0.01). Notably, P80+ were significantly less satisfied with information about the short and long-term side effects of BC therapies and managing toxicities. P80+ were also less likely to have participated in a clinical trial (p< 0.001) or to want to do so in the future (p= 0.0001). Conclusions: Although P80+ experienced less anxiety and symptom-related distress compared with P80−, they were significantly less satisfied with information regarding the side effects of BC therapies and their management. P80+ were significantly less likely to have participated in a clinical trial or be open to considering this option. Future studies should address educational needs pertaining to side effects and barriers to research participation in P80+.
背景：目前指导80岁及以上（P80+）乳腺癌患者治疗方案的循证数据有限。识别并解决未满足的需求至关重要。目的：Advocate-BREAST80+研究比较了P80+患者与80岁以下（P80-）患者的需求差异。方法：2021年12月，通过电子方式向梅奥诊所乳腺疾病登记库中的6918名参与者发放REDCap调查问卷。该调查询问了患者对乳腺癌诊疗多方面的关注点及满意度。结果：共有2437名参与者完成调查（回复率35%），其中202人（8.3%）为P80+患者。与P80-患者相比，P80+患者接受局部区域治疗和全身治疗的比例显著更低（p<0.01）。值得注意的是，P80+患者对乳腺癌治疗短期与长期副作用相关信息及毒性管理的满意度显著较低。此外，P80+患者参与临床试验的比例更低（p<0.001），且未来参与意愿显著更低（p=0.0001）。结论：尽管P80+患者相较于P80-患者经历更少的焦虑和症状相关困扰，但其对乳腺癌治疗副作用及相关管理信息的满意度显著更低。P80+患者参与临床试验的可能性显著更低，且对该选项持开放态度的意愿更低。未来研究应重点关注该群体在副作用教育需求及临床研究参与障碍方面的问题。
肿瘤(癌症)患者之家